{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=14",
    "query": {
      "intervention": "Placebo solution",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 3135,
    "total_pages": 314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T08:27:02.392Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04485949",
      "title": "A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "IGV-001 Cell Immunotherapy",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Standard of Care (SOC): Radiation Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "SOC: Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Imvax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 99,
      "start_date": "2023-03-20",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 23,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Detroit, Michigan + 15 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485949"
    },
    {
      "nct_id": "NCT06194851",
      "title": "Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Traumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Oxytocin nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Saline nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Brief Cognitive-Behavioral Conjoint Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2024-10-28",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06194851"
    },
    {
      "nct_id": "NCT06699849",
      "title": "Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease Vaso-occlusive Crisis"
      ],
      "interventions": [
        {
          "name": "CSL889",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-07-10",
      "completion_date": "2027-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 20,
      "location_summary": "Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699849"
    },
    {
      "nct_id": "NCT00362869",
      "title": "Enteroaggregative E.Coli (EAEC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Escherichia Coli Infections"
      ],
      "interventions": [
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Enteroaggregative E. coli (EAEC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-02",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-26",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362869"
    },
    {
      "nct_id": "NCT00623363",
      "title": "Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "piclozotan",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride (normal saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2007-07-13",
      "completion_date": "2008-07-17",
      "has_results": true,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 5,
      "location_summary": "Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623363"
    },
    {
      "nct_id": "NCT05891587",
      "title": "Semaglutide Therapy for Alcohol Reduction - Tulsa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oklahoma State University Center for Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-07-07",
      "completion_date": "2025-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891587"
    },
    {
      "nct_id": "NCT01194414",
      "title": "A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tocilizumab SC",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab IV",
          "type": "DRUG"
        },
        {
          "name": "placebo to tocilizumab SC",
          "type": "DRUG"
        },
        {
          "name": "placebo to tocilizumab IV",
          "type": "DRUG"
        },
        {
          "name": "Disease-modifying antirheumatic drugs (DMARDs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1262,
      "start_date": "2010-09",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-06-20",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 54,
      "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194414"
    },
    {
      "nct_id": "NCT03244644",
      "title": "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clostridium Difficile Infection (CDI)"
      ],
      "interventions": [
        {
          "name": "RBX2660",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open label RBX2660 (only for confirmed CDI recurrence)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebiotix Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2017-07-31",
      "completion_date": "2020-08-03",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 60,
      "location_summary": "Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03244644"
    },
    {
      "nct_id": "NCT02831387",
      "title": "Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "P-321 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "P-321 Ophthalmic Solution placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Parion Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 47,
      "start_date": "2016-07",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-10-11",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 7,
      "location_summary": "Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Washington",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831387"
    },
    {
      "nct_id": "NCT03331965",
      "title": "Metoclopramide Versus Placebo for GJ Placement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Radiation Exposure",
        "Enteral Nutrition"
      ],
      "interventions": [
        {
          "name": "Metoclopramide 5 MG/ML Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2018-04-09",
      "completion_date": "2019-10-03",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-10-18T08:27:02.392Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03331965"
    }
  ]
}